Top Markets
#1 AI XOVIA AI XOVIA +34.12%
#2 Zora Zora +23.98%
#3 Seeker Seeker +22.89%
#4 Full Moon Full Moon +18.71%
#5 Axelar Axelar +15.12%
#6 rsERG rsERG +14.92%
#7 Ergo Ergo +13.46%
#8 0G 0G +10.86%
#9 Notcoin Notcoin +10.67%
#10 VVS Finance VVS Finance +10.62%
Coin of the day
AI XOVIA AI XOVIA
Settings
Language
ENGLISH
Currency
USD
Theme
Eikon Therapeutics, Inc. Common Stock Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

EIKN
Rank in Stocks #12327
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Share Price
$11.03
Last synced: 2026-08-28
Market Cap
$597.15M
Change (1 day)
-4.25%
Change (1 year)
-
Country
US
Trade Eikon Therapeutics, Inc. Common Stock (EIKN)

Category

Healthcare
Revenue for Eikon Therapeutics, Inc. Common Stock (EIKN)
Revenue in Aug 2026 TTM: 0
According to Eikon Therapeutics, Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eikon Therapeutics, Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH